Search Results - "Villano, S.A."

[50] ANTIVIRAL ACTIVITY OF THE NON-NUCLEOSIDE POLYMERASE INHIBITOR, HCV-796, IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2b IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV by Villano, S.A, Raible, D, Harper, D, Speth, J, Chandra, P, Shaw, P, Bichier, G

Get full text

A Randomized, Double‐Blind, Pharmacokinetic Study of Oral Maribavir with Tacrolimus in Stable Renal Transplant Recipients by Pescovitz, M. D., Bloom, R., Pirsch, J., Johnson, J., Gelone, S., Villano, S. A.

“…Maribavir is being developed as a novel agent for the prevention or treatment of cytomegalovirus infections after stem cell and organ transplantation. This was…”
Get full text

Single and multiple dose pharmacokinetics (PK) of maribavir (MB) in healthy adults by Ma, J.D., Nafziger, A.N., Villano, S.A., Victory, J., Bertino, J.S.

“…Background MB is an oral antiviral agent with activity against cytomegalovirus (CMV). Single and multiple dose PK of MB were examined in healthy adults as part…”
Get full text

Effect of the anti-cytomegalovirus (CMV) drug maribavir (MB) on the activities of cytochrome p450 (CYP) 1A2, 2C9, 2C19, 2D6, 3A, N-ACETYLTRANSFERASE-2 (NAT-2), and xanthine oxidase (XO) as assessed by the cooperstown 5+1 drug cocktail by Ma, J.D., Nafziger, A.N., Villano, S.A., Gaedigk, A., Victory, J., Bertino, J.S.

“…Background The effect of repeated dose oral MB on CYP1A2, 2C9, 2C19, 2D6, 3A, NAT‐2, and XO activity were evaluated in healthy volunteers. Methods A drug…”
Get full text